M&A activity of Sanofi and Bioverative for rare blood diseases
Sanofi has strengthened its position in hematology & speciality medicine by acquiring Bioverativ, Biogen hemophilia & blood disorders-focused company for USD 105 per share on March 8, 2018. This will increase Sanofi’s hemophilia portfolio for the treatment of hemophilia A and hemophilia B.
Netherlands biotech Escalier gets USD 19 Million for pivotal dermatology assessments
New Science Ventures, BioGeneration Ventures and European VC firm Forbion to raise USD 19 million for the development of drugs for Escalier Biosciences. This financial partnership will develop the treatment for dermatologic, p...
